## Jan Steffel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3103026/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
2	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	1.0	1,576
3	Drug-Eluting Stent and Coronary Thrombosis. Circulation, 2007, 115, 1051-1058.	1.6	850
4	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	0.7	494
5	Tissue Factor in Cardiovascular Diseases. Circulation, 2006, 113, 722-731.	1.6	439
6	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2017, 14, 1375-1379.	0.3	251
7	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018, 20, 1231-1242.	0.7	194
8	Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression. Circulation, 2005, 112, 2002-2011.	1.6	158
9	Histamine Induces Tissue Factor Expression. Circulation, 2005, 112, 341-349.	1.6	133
10	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
11	Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH 2 Kinase Phosphorylation. Circulation, 2005, 111, 1685-1689.	1.6	111
12	Paclitaxel Enhances Thrombin-Induced Endothelial Tissue Factor Expression via c-Jun Terminal NH 2 Kinase Activation. Circulation Research, 2006, 99, 149-155.	2.0	110
13	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
14	Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation. Circulation, 2006, 114, 1512-1521.	1.6	97
15	Electrocardiographic Characteristics at Initial Diagnosis in Patients With Isolated Left Ventricular Noncompaction. American Journal of Cardiology, 2009, 104, 984-989.	0.7	95
16	Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. European Heart Journal, 2010, 31, 236-242.	1.0	66
17	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
18	First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia. Radiotherapy and Oncology, 2020, 152, 203-207.	0.3	59

Jan Steffel

#	Article	IF	CITATIONS
19	Results of the Patient-Related Outcomes of Mechanical lead Extraction Techniques (PROMET) study: a multicentre retrospective study on advanced mechanical lead extraction techniques. Europace, 2020, 22, 1103-1110.	0.7	57
20	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. European Heart Journal, 2015, 36, 2780-2789.	1.0	55
21	Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre. Heart, 2011, 97, 1668-1674.	1.2	50
22	Superresponse to Cardiac Resynchronization Therapy. Circulation, 2014, 130, 87-90.	1.6	50
23	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	1.2	45
24	Non-vitamin K oral anticoagulants in â€~valvular' atrial fibrillation: a call for action. Europace, 2016, 18, 1-3.	0.7	44
25	Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population. Clinical Therapeutics, 2019, 41, 107-117.	1.1	43
26	Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace, 2009, 11, 1193-1200.	0.7	41
27	Drug-eluting stents—what should be improved?. Annals of Medicine, 2008, 40, 242-252.	1.5	37
28	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f30-f39.	1.4	33
29	Cyclooxygenase-2 Inhibition and Coagulation. Journal of Cardiovascular Pharmacology, 2006, 47, S15-S20.	0.8	31
30	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	0.8	30
31	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovascular Disorders, 2019, 19, 165.	0.7	29
32	Rhythm disorders in isolated left ventricular noncompaction. Annals of Medicine, 2012, 44, 101-108.	1.5	28
33	Cocaine unbalances endothelial tissue factor andÂtissue factor pathway inhibitor expression. Journal of Molecular and Cellular Cardiology, 2006, 40, 746-749.	0.9	25
34	Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. Europace, 2022, 24, 1119-1126.	0.7	25
35	Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. Journal of Cardiovascular Medicine, 2019, 20, 97-104.	0.6	24
36	Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Journal of Cardiovascular Medicine, 2009, 10, 616-623.	0.6	23

JAN STEFFEL

#	Article	IF	CITATIONS
37	Stroke prevention in atrial fibrillation: re-defining â€~real-world data' within the broader data universe. European Heart Journal, 2018, 39, 2932-2941.	1.0	22
38	Stereotactic radioablation of ventricular arrhythmias in patients with structural heart disease – A systematic review. Radiotherapy and Oncology, 2021, 162, 132-139.	0.3	22
39	2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment—Authors' reply. Europace, 2021, 23, 1685-1686.	0.7	22
40	Long-Term Follow-up of Patients With Isolated Left Ventricular Noncompaction - Role of Electrocardiography in Predicting Poor Outcome Circulation Journal, 2011, 75, 1728-1734.	0.7	21
41	Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice—an underestimated complication?. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 219-226.	0.6	20
42	Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. International Journal of Cardiology, 2018, 260, 82-87.	0.8	20
43	Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	19
44	First experience with edoxaban and atrial fibrillation ablation – Insights from the ENGAGE AF-TIMI 48 trial. International Journal of Cardiology, 2017, 244, 192-195.	0.8	19
45	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	0.7	18
46	Devices in Heart Failure Patients—Who Benefits From ICD and CRT?. Frontiers in Cardiovascular Medicine, 2019, 6, 111.	1.1	17
47	Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. International Journal of Cardiology, 2015, 185, 250-255.	0.8	15
48	Clinical performance of a new bidirectional rotational mechanical lead extraction sheath. Europace, 2016, 18, 253-256.	0.7	15
49	Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators: A propensity-matched analysis from a multicenter European registry. Heart Rhythm, 2022, 19, 1109-1115.	0.3	15
50	Incidence and Prognosis of Ventricular Arrhythmias in Patients with Congenital Left Ventricular Aneurysms or Diverticula. American Journal of Medicine, 2015, 128, 653.e1-653.e6.	0.6	13
51	Insertion of miniaturized cardiac monitors outside the catheter operating room: experience and practical advice. Europace, 2017, 19, 1624-1629.	0.7	13
52	Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 349, 597-603.	1.0	11
53	A square root pattern of changes in heart rate variability during the first year after circumferential pulmonary vein isolation for paroxysmal atrial fibrillation and their relation with long‑term arrhythmia recurrence. Kardiologia Polska, 2020, 78, 209-218.	0.3	10
54	Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. European Heart Journal, 2017, 38, ehw578.	1.0	9

JAN STEFFEL

#	Article	IF	CITATIONS
55	Comprehensive cardiac resynchronization therapy optimization in the real world. Cardiology Journal, 2014, 21, 316-324.	0.5	9
56	Does implantation technique infl uence lead failure?. Acta Cardiologica, 2015, 70, 581-586.	0.3	8
57	Compression coil provides increased lead control in extraction procedures. Europace, 2015, 17, 499-503.	0.7	8
58	†Ten Commandments' of the EHRA Guide for the Use of NOACs in AF. European Heart Journal, 2018, 39, 1322-1322.	1.0	8
59	Predictors of left atrial fibrosis in patients with atrial fibrillation referred for catheter ablation. Cardiology Journal, 2022, 29, 413-422.	0.5	7
60	The Subcutaneous Implantable Cardioverter Defibrillator. European Heart Journal, 2017, 38, 226-228.	1.0	6
61	Current practice of cardiac resynchronization therapy (CRT) in the real world: insights from the European CRT survey. European Heart Journal, 2009, 30, 2433-2435.	1.0	5
62	Long-Term Performance of Modern Coronary Sinus Leads in Cardiac Resynchronization Therapy. Indian Pacing and Electrophysiology Journal, 2014, 14, 112-120.	0.3	5
63	The subcutaneous ICD for prevention of sudden cardiac death: Current evidence and future directions. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1421-1427.	0.5	5
64	Extraction of a leadless pacemaker 23 months after implantation. European Heart Journal, 2020, 41, 2038-2038.	1.0	5
65	Persistent left superior vena cava transvenous lead extraction: A European experience. Journal of Cardiovascular Electrophysiology, 2021, , .	0.8	5
66	Outcome of super-responders to cardiac resynchronization therapy defined by endpoint-derived parameters of left ventricular remodeling: a two-center retrospective study. Clinical Research in Cardiology, 2015, 104, 136-144.	1.5	4
67	Case Report: Newâ€Onset Retinal Migraine After Transseptal Catheterization. Headache, 2020, 60, 463-468.	1.8	4
68	Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a longâ€ŧerm retrospective cohort study. ESC Heart Failure, 2020, 7, 2773-2783.	1.4	4
69	Transvenous lead extraction: The influence of age on patient outcomes in the PROMET study cohort. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1540-1548.	0.5	4
70	Mechanical dyssynchrony in CRT: still searching for the Holy Grail. European Heart Journal, 2014, 35, 13-15.	1.0	3
71	The year in cardiology 2017: arrhythmias and cardiac devices. European Heart Journal, 2018, 39, 434-441.	1.0	3
72	Dose adjustment based on the plasma level measurement used anti-FXa chromogenic assay on the use of non-vitamin K antagonist oral anticoagulants (NOACs) improved the overall benefit of NOACs dosing in patients with atrial fibrillation: Authors' reply. Europace, 2021, 23, 1686-1687.	0.7	3

Jan Steffel

#	Article	IF	CITATIONS
73	Results of transvenous lead extraction of coronary sinus leads in patients with cardiac 4,703 resynchronization therapy. Chinese Medical Journal, 2013, 126, 4703-6.	0.9	3
74	Completely Epicardial Implantation of a Cardiac Resynchronization Therapy Defibrillator Using a Minimal Invasive Approach. Thoracic and Cardiovascular Surgeon, 2014, 62, 070-072.	0.4	2
75	Stroke Prevention with Non-Vitamin K Oral Anticoagulants: For Most, but Not for All!. Cardiology, 2019, 143, 121-123.	0.6	2
76	Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drug–drug interaction. European Heart Journal, 2019, 40, 3802-3802.	1.0	2
77	Acute Hemoptysis and Bronchoscopic Follow-up After Cryoablation of the Pulmonary Veins. Journal of Bronchology and Interventional Pulmonology, 2019, 26, e37-e40.	0.8	2
78	The year in cardiology: arrhythmias and pacing. European Heart Journal, 2020, 41, 619-625c.	1.0	2
79	Assessment of injury current during leadless pacemaker implantation. International Journal of Cardiology, 2021, 323, 113-117.	0.8	2
80	Right ventricular only pacing for cardiac resynchronization therapy. Europace, 2022, 24, 70-71.	0.7	2
81	Long-term follow-up after cardiac resynchronization therapy-optimization in a real-world setting: A single-center cohort study. Cardiology Journal, 2021, 28, 728-737.	0.5	2
82	The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices. European Heart Journal, 2017, 38, ehw629.	1.0	1
83	The year in cardiology 2018: arrhythmias and cardiac devices. European Heart Journal, 2019, 40, 803-808.	1.0	1
84	Idarucizumab in the â€~real world': possibilities and limitations. Europace, 2019, 21, 359-360.	0.7	1
85	The subcutaneous implantable cardioverter defibrillator in daily clinical practice. Swiss Medical Weekly, 2017, 147, w14518.	0.8	1
86	Patient Related Outcomes of Mechanical lead Extraction Techniques (PROMET) study: A comparison of two professions. PACE - Pacing and Clinical Electrophysiology, 2022, , .	0.5	1
87	An Unusual Reason for Loss of Biventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 383-386.	0.5	0
88	Magnetic field interaction between a left ventricular assist device controller and a cardiac resynchronization therapy-defibrillator. Europace, 2015, 17, 1719-1719.	0.7	0
89	The year in cardiology 2015: arrhythmias and device therapy. European Heart Journal, 2016, 37, 587-593.	1.0	0
90	Atypical presentation of false asystole detection in implantable loop recorder. BMJ Case Reports, 2017, 2017, bcr-2017-221280.	0.2	0

JAN STEFFEL

#	Article	IF	CITATIONS
91	Exercise intolerance — from spiroergometry to transdiaphragmatic myocardial punch biopsy: a case report of isolated cardiac sarcoidosis. European Heart Journal - Case Reports, 2021, 5, ytaa121.	0.3	0
92	Leadless pacemaker tools used beyond device implantation. HeartRhythm Case Reports, 2021, 7, 83-86.	0.2	0
93	Distinctive characteristics of his bundle potentials in patients with atrioventricular nodal reentrant tachycardia. Cardiology Journal, 2021, , .	0.5	0
94	Providing practical answers to practical questions for NOAC therapy. Cardiology Journal, 2018, 25, 441-442.	0.5	0
95	The year in cardiology: arrhythmias and pacingâ€The year in cardiology 2019. Cardiologia Croatica, 2020, 15, 132-145.	0.0	0